About Hypha Discovery
Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and new derivatives of drugs and agrochemicals in discovery and development. Hypha is an expert in the scalable synthesis and purification of drug metabolites and oxidised derivatives of lead compounds, and possesses a wealth of experience in the production, purification and structure elucidation of natural products.
One-Stop Metabolite Shop
Hypha recently launched the “One Stop Metabolite Shop” which offers clients the opportunity to access phase I and phase II metabolites, from microgram scale for MetID through to multi mg / gram scale for further evaluation and provision of bioanalytical standards.
We offer a comprehensive suite of techniques for provision of even the most difficult-to-synthesise metabolite, comprising chemical synthesis, recombinant enzymes such as PolyCYPs, microbial biotransformation, mammalian liver fractions as well as the purification of metabolites from biological matrices. Hypha scientists are also experts in structural elucidation via NMR spectroscopy.
NEW PolyCYPs®+ biocatalysis kits
PolyCYPs®+ is a new product comprising 18 PolyCYP isoforms and broadened by the addition of other phase I enzymes. Human aldehyde oxidase (AOX1) and the main human hepatic flavin-containing monooxygenase (FMO3) are now included in the kit, with other human FMO isoforms available soon. Inclusion of new PolyCYPs isoforms broadens coverage of reactions, and have been proven to metabolise some low turnover drugs and produce multi-step oxidised metabolites.
Download an info sheet on PolyCYPs+
Click here to find out more about PolyCYPs+ kits
NEWS & EVENTS
WEBINARS – If you missed the recent webinars on Hypha’s new “One-stop metabolite shop” featuring our enhanced PolyCYPs+ kit and a newly developed late-stage chemical glucuronidation screen, contact us for a link to a recording.
9th – 10th December 2019, University of Warwick, UK Dr Vincent Poon, Hypha’s Senior Molecular Biologist, will be presenting a poster on “Improvement of PolyCYPs® microbial cytochrome P450 cell factory for efficient whole-cell biotransformation” joint with collaborating scientists at University College London
18th – 19th February 2020, Manchester, UK Hypha will be giving a talk on LSF using PolyCYPs enzymes Hypha’s PolyCYPs enzymes have been routinely used by pharma and agchem companies for producing metabolites. One application involves direct comparison of radiometric profiles of PolyCYPs and regulatory study samples. In this study by Charles River, a radiolabelled agrochemical compound was incubated with PolyCYPs and the metabolites matched with those detected in goat faeces, as part of an mass balance and disposition study, thereby providing an immediate route to access and scale-up metabolites. Click here for a link to an illustration of the results of this study.Come and meet us at the following events
Synthetic Biology UK 2019
SCI/RSC Applied Late-stage Functionalisation: Where Chemistry meets Biology
Hypha’s latest metabolite project update
Our brochure on drug metabolites and C-H activated derivatives is now available. Inside we feature interesting case studies and client projects, including the following topics: Let us know if you would like a copy of a paper published last year in Xenobiotica entitled Microbial Biotransformation – An Important Tool for the Study of Drug Metabolism, which describes some interesting projects Hypha have undertaken for Merck and Janssen with several difficult-to-synthesise hydroxylated and glucuronidated metabolites. Read the abstract at http://bit.ly/2xb6H9d In a recent newsletter we described a case study illustrating the use of microbial biotransformation to produce scalable quantities of glucuronides, focusing on the synthesis of acyl glucuronides of carboxylic acid-containing drugs. Access a pdf of the newsletter on glucuronides of carboxylic acid-containing drugsDownload a copy of our brochure on drug metabolites and C-H activated derivatives
